A little-known biotech firm focused on Traditional Chinese Medicine has surged over 64,000%, catapulting its valuation to nearly $10 billion. Is this a biotech breakthrough, a speculative frenzy, or something in between?
Join Dan Koh and Ryan Huang as they dissect the rise of Regencell Bioscience Holdings Limited — a company with just 12 employees, no FDA-approved products, and a CEO earning $1 a year.

Mind Your Business: How Decibelist is turning everyday objects into Art Speakers
14:53

Bigger Pic: Are stocks too optimistic as oil prices rise and risks build
12:42

Companies To Watch: L’Oréal results highlight resilient beauty demand
09:58